Tag Archives | pharmacogenomics

BIO International Convention 2017 Updates #2-BIG Data Drives Precision Medicine

 Big Data Provides Pathway to Precision Medicine Description of Track Speaker Atul Butte, MD,Ph.D. Director, UCSF Institute for Computational Health Sciences The remarkable ascent of Big Data for example from biomedical imaging, next generation sequencing and adjacent technologies that deliver a multiplicity of heterogeneous data has been a tremendous boon for basic biomedical research and […]

Continue Reading 0

Biotechs Mired in a Trading Range: Breakout Delayed…Update-3

Update-3…ASCO Movers Today 5/18:  IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the “Trump Trade” (industrials and materials).  Mid-caps and small caps were very strong. Large Caps: MRK up 1.35%,REGN up 2.38%. Mid Caps: […]

Continue Reading 0

Large Cap Biopharmaceutical Valuations: Q1 2017

May 8, 2017  Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%.  The large cap focused IBB […]

Continue Reading 0

Rayno Biobeat #3 2017 Biotech Breakout Coming-Update-2

Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1… 5/8/17…Biotech Sector Losing Momentum XBI down 4.3% over 5 days although still up 15.5% YTD. IBB very weak today down over 2%. NASDAQ Composite and QQQ holding near highs mainly because of strength in […]

Continue Reading 0

Biotechs Running Again: Rayno Life Science Stocks-See Picks…Earnings Updates

Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for EPS was confirmed at $5.44-5.54. Stock closed up 1.55% today to $66.05. Alexion […]

Continue Reading 0

Biotech Stocks Sink with Broad Sell-Off on Political Realities…Updates

3/22 Update after close..Relief Rally Awaiting Tomorrow’s Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump Comments Uncertainty Mounts for GOP Healthcare Plan-Fewer Patients Higher Costs? Worse Day of the Year […]

Continue Reading 0

Rayno BioBeat 2017 #2: Biotech Breakthrough Rally

2017 Biotech Breakthrough on a Green Screen Day Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance. Our favorite trading pick the XBI soared 4.82% to $70.48 breaking through the September top and 19% up YTD. The large cap IBB went up 2.89% to […]

Continue Reading 0

Biotech ETFs: Fidelity Biotech Fund Outperforms IBB but XBI is Still the Leader

Fidelity Biotech Portfolio (FBIOX) Is Beginning to Show Benefits of Active Management Biotech stocks have outperformed the market YTD despite a bit of a sell-off recently. During the bubblicious momentum days of 2015 when biotech was on a tear major biotech ETFs outperformed mutual funds. After two severe corrections in 2016 the Fidelity Select Biotechnology […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

2017 J.P.Morgan Healthcare Conference: Large Cap Biotechs Compared to 2016

Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat. Selected stocks that continued their upward trend from earlier this week are: Array Biopharma (ARRY) up 7.3%  -Five […]

Continue Reading 0